GNC-035 is under clinical development by Systimmune and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GNC-035’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GNC-035 is under development for the treatment of solid tumor, triple negative breast caner, lung cancer, gastric cancer, ovarian cancer, advanced or metastatic breast cancer, leukemia, lymphoma, relapsed or refractory non-Hodgkin’s lymphoma, relapsed or refractory chronic lymphocytic leukemia (CLL/SLL), relapsed or refractory acute B-lymphocytic leukemia, relapsed or refractory acute myeloid leukemia and relapsed or refractory philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. The therapeutic candidate is a tetra specific octavalent, which acts by targeting ROR1, PDL1, 4-1BB and CD3. It is administered through intravenous route.
It was also under development for the treatment of relapsed or refractory hematological tumor.
Systimmune is a biopharmaceutical company that develops novel therapies for the treatment of cancer. The company’s technology platforms for the discovery and development of novel bio-therapeutics include antibody discovery platform to manufacture target-specific IgG producing B cells using novel miniaturized immuno-assays; process development platform to manufacture bio-therapeutics and multi-specific antibody engineering platforms. Its pipeline portfolio include bi-specific antibodies, antibody conjugates, and immuno-oncology products for the treatment of non-small cell lung cancer, glioblastoma, colon, neck, head, breast, nasopharyngeal, kidney and liver cancers. These antibodies act through systematic intervention to trigger the immune response on the cancer cells. Systimmune is headquartered in Redmond, Washington, the US.
For a complete picture of GNC-035’s drug-specific PTSR and LoA scores, buy the report here.